Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (211-220 of 223) with videos related to

Pageof 23
Sort By:
The Journal of Investigative Dermatology|November 13, 2019
Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic TherapyShunya Mashiko, Rebecca M Edelmayer, Yingtao Bi, et al.
JAMA Dermatology|October 13, 2021
Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical TrialKristina M Harris, Dawn E Smilek, Margie Byron, et al.
Lancet (London, England)|November 28, 2025
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trialsEmma Guttman-Yassky, Kenji Kabashima, Margitta Worm, et al.
JAMA Dermatology|December 27, 2019
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical TrialMargitta Worm, Eric L Simpson, Diamant Thaçi, et al.
The British Journal of Dermatology|July 3, 2026
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 TrialsLinda Stein Gold, April W Armstrong, Jennifer Soung, et al.
The Journal of Investigative Dermatology|December 18, 2023
Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum in Clinical Trials: A Delphi Consensus on Behalf of the UPGRADE (Understanding Pyoderma Gangrenosum: Review and Assessment of Disease Effects) GroupKanika Kamal, Eric Xia, Sara J Li, et al.
Experimental Dermatology|April 2, 2015
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasisKristian Reich, Kim A Papp, Robert T Matheson, et al.
Journal of the American Academy of Dermatology|August 3, 2019
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension studyMette Deleuran, Diamant Thaçi, Lisa A Beck, et al.
Lancet (London, England)|September 21, 2025
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trialsLinda Stein Gold, April W Armstrong, Robert Bissonnette, et al.
The British Journal of Dermatology|September 9, 2024
A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema CouncilCarter Haag, Andrew Alexis, Valeria Aoki, et al.
Pageof 23

Showing results (211-220 of 223) with videos related to

Sort By:
Pageof 23
The Journal of Investigative Dermatology|November 13, 2019
Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic TherapyShunya Mashiko, Rebecca M Edelmayer, Yingtao Bi, et al.
JAMA Dermatology|October 13, 2021
Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical TrialKristina M Harris, Dawn E Smilek, Margie Byron, et al.
Lancet (London, England)|November 28, 2025
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trialsEmma Guttman-Yassky, Kenji Kabashima, Margitta Worm, et al.
JAMA Dermatology|December 27, 2019
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical TrialMargitta Worm, Eric L Simpson, Diamant Thaçi, et al.
The British Journal of Dermatology|July 3, 2026
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 TrialsLinda Stein Gold, April W Armstrong, Jennifer Soung, et al.
The Journal of Investigative Dermatology|December 18, 2023
Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum in Clinical Trials: A Delphi Consensus on Behalf of the UPGRADE (Understanding Pyoderma Gangrenosum: Review and Assessment of Disease Effects) GroupKanika Kamal, Eric Xia, Sara J Li, et al.
Experimental Dermatology|April 2, 2015
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasisKristian Reich, Kim A Papp, Robert T Matheson, et al.
Journal of the American Academy of Dermatology|August 3, 2019
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension studyMette Deleuran, Diamant Thaçi, Lisa A Beck, et al.
Lancet (London, England)|September 21, 2025
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trialsLinda Stein Gold, April W Armstrong, Robert Bissonnette, et al.
The British Journal of Dermatology|September 9, 2024
A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema CouncilCarter Haag, Andrew Alexis, Valeria Aoki, et al.
Pageof 23